Shampoo plus conditioner: the secret to fighting dandruff?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At baseline: A moderate to severe level of squames: Total squames score (adherent + non-adherent) \> 4 (ranging from 0 to 10) including an adherent squames score ≥ 2.5 (ranging from 0 to 5) and no limit for non-adherent squames score at inclusion (groups must be equilibrating); * Patient with hair length \> 2 cm; * Patient having received the information about the study modalities and having given his/her written consent and having signed the "informed consent form" specific for this study, in accordance with the corresponding procedure; * Patient usually using a shampoo 2 to 3 times a week and accepting to follow this rate during the whole study period; * Patient having stopped any possible soothing, anti-dandruff and anti-hair loss treatment (per os or topical) 2 weeks prior to study beginning D-14; * Patient agreeing not to use any other hair product other than the ones provided for the study (till the end of study) in particular: * no styling product (tonic, spray, lotion, foam) three days before the study visit; * no treating haircare product (conditioner, hair mask, non-rinsed hair care product, oil,….); * no anti-scales products (whatever the type: shampoo, treatment..); * no hair colouring or hair bleaching within one week prior to any study visit. Exclusion Criteria: * Subject with psoriasis; * Pregnancy, breast feeding, childbearing potential without adequate contraception, or irregular menstrual cycles; * History of drug or alcohol abuse; * History or suspicion of unreliability, poor cooperation or noncompliance with medical treatment; * Topical treatment of the scalp with other antifungal medication or with corticosteroids in the last 3 weeks before start of the study; * Systemic use of retinoids, erythromycin, tetracycline or any of its derivatives, trimethoprim/sulfamethoxazole, or metronidazole within 28 days before the start of the study. * Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol; * Clinical signs and/or history of immunosuppression; * Severe disease (e.g. cancer, cardiac infarct, unstable angina pectoris); * Treatment with any other investigational drug in the 4 weeks prior to study entry.